Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Scalfari

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2015
Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NOAntonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2019
MS progression is predominantly driven by age-related mechanisms - YESAntonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 20, 2021
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - YesAntonio Scalfari
Brain : a Journal of Neurology|September 1, 2010
Predicting a window of therapeutic opportunity in multiple sclerosisGeorge Ebers, Martin Daumer, Antonio Scalfari
Brain : a Journal of Neurology|February 10, 2011
Reply to Oluf Anderson's reply: Predicting a window of therapeutic opportunity in multiple sclerosisGeorge Ebers, Martin Daumer, Antonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 17, 2018
Prognostic information for people with MS: Impossible or inevitable?Christoph Heesen, Antonio Scalfari, Ian Galea
Neurology|March 16, 2011
Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MSGeorge C Ebers, Martin Daumer, Antonio Scalfari
Current Opinion in Neurology|March 4, 2021
Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patientsMassimiliano Calabrese, Damiano Marastoni, Francesco Crescenzo, et al.
Brain : a Journal of Neurology|February 3, 2026
A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosisPaolo A Muraro, Eleonora De Matteis, Antonio Scalfari
Journal of Neurology, Neurosurgery, and Psychiatry|June 2, 2026
Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis?Marc Pawlitzki, Lars Masanneck, Antonio Scalfari, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2015
Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NOAntonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2019
MS progression is predominantly driven by age-related mechanisms - YESAntonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 20, 2021
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - YesAntonio Scalfari
Brain : a Journal of Neurology|September 1, 2010
Predicting a window of therapeutic opportunity in multiple sclerosisGeorge Ebers, Martin Daumer, Antonio Scalfari
Brain : a Journal of Neurology|February 10, 2011
Reply to Oluf Anderson's reply: Predicting a window of therapeutic opportunity in multiple sclerosisGeorge Ebers, Martin Daumer, Antonio Scalfari
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 17, 2018
Prognostic information for people with MS: Impossible or inevitable?Christoph Heesen, Antonio Scalfari, Ian Galea
Neurology|March 16, 2011
Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MSGeorge C Ebers, Martin Daumer, Antonio Scalfari
Current Opinion in Neurology|March 4, 2021
Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patientsMassimiliano Calabrese, Damiano Marastoni, Francesco Crescenzo, et al.
Brain : a Journal of Neurology|February 3, 2026
A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosisPaolo A Muraro, Eleonora De Matteis, Antonio Scalfari
Journal of Neurology, Neurosurgery, and Psychiatry|June 2, 2026
Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis?Marc Pawlitzki, Lars Masanneck, Antonio Scalfari, et al.
Pageof 5